Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,232 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SARS CoV 2 Virus Clear all
No Longer Available No phase listed Expanded access

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

NCT05235347
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance

NCT06698497
View directory record Official record
Conditions
Vaccine Uptake
Interventions
Communication Campaign
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

NCT05212610
View directory record Official record
Conditions
COVID-19, Corona Virus Infection
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Not listed Not applicable Interventional

[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse

NCT04719208
View directory record Official record
Conditions
Covid19
Interventions
Water (E) Mouth rinse with the solution provided, Chlorhexidine gluconate (A) Mouth rinse with the solution provided, Hydrogen peroxide (B) Mouth rinse with the solution provided, Betadine (C) Mouth rinse with the solution provided, Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Multimodal Investigation of Post COVID-19 in Females

NCT05225220
View directory record Official record
Conditions
Post COVID-19, Cognitive Dysfunction
Interventions
Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)
Device
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Not listed Phase 2 Interventional

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

NCT04646603
View directory record Official record
Conditions
COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions
MRG-001, Placebo
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

NCT06402318
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions
A&M Breathalyzer PROTECT Kiosk
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

NCT05403346
View directory record Official record
Conditions
SARS-CoV-2, Covid19
Interventions
CoviDx™ Covid-19 Antigen Self-Test
Device
Lead sponsor
Lumos Diagnostics
Industry
Eligibility
2 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Nasal Swab Objective and Statistical Evaluation (NOSE Study)

NCT07469670
View directory record Official record
Conditions
SARS Coronavirus 2 RT-PCR Testing
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Flu COVID Vaccine Views

NCT07871448
View directory record Official record
Conditions
Influenza, COVID-19, Vaccination Willingness
Interventions
Survey
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 89 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients

NCT04524507
View directory record Official record
Conditions
COVID-19
Interventions
High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

NCT04472611
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of Care (SOC) and Colchicine+Rosuvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

COVID-19 Transmission and Morbidity in Malawi

NCT05973084
View directory record Official record
Conditions
SARS CoV 2 Infection, SARS CoV 2 Vaccination
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
5 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Active, not recruiting No phase listed Observational

Pain in Long COVID-19: the Role of Sleep

NCT05606211
View directory record Official record
Conditions
Long COVID
Interventions
No intervention
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19

NCT04707534
View directory record Official record
Conditions
Covid19
Interventions
Dexamethasone
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

NCT04488575
View directory record Official record
Conditions
Covid19
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

NCT04323761
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

NCT05366322
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Not listed No phase listed Observational

Acute Encephalopathy in Critically Ill Patients With COVID-19

NCT04320472
View directory record Official record
Conditions
COVID-19, Encephalopathy, Critically Ill
Interventions
Follow up
Other
Lead sponsor
Ictal Group
Other
Eligibility
18 Years and older
Enrollment
250 participants
Timeline
2020
U.S. locations
2
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 4:53 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients

NCT04950673
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome, COVID Long-Haul
Interventions
Cognivue
Device
Lead sponsor
Cognivue, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Irvine, California • Visalia, California • Boca Raton, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

NCT07095231
View directory record Official record
Conditions
COVID-19
Interventions
STX-S
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

NCT04473183
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, SARS-CoV-2, Corona Virus Infection
Interventions
Specimen Collection, Surveys
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population

NCT04561102
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Diagnostic test for detection of SARS-CoV-2
Diagnostic Test
Lead sponsor
Illumina, Inc.
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 17, 2026, 4:53 AM EDT